



## Press release

### Response to the Ukraine crisis

Freiburg, March 18th, 2021

#### **Dr. Falk Pharma supports APOTHEKER HELFEN e.V. with extensive donation of IBD medicines for Ukraine.**

Together with the world, Dr. Falk Pharma is watching the events in Ukraine and the threat to global peace and stability with great concern. Our hearts go out to the people in Ukraine suffering under the impacts of war. Our thoughts are also with the employees of our Ukrainian partner and their families.

#### **Together we do more**

Providing patients suffering from IBD or digestive and metabolic diseases with medicines is very important to us. However, due to the difficult situation inside Ukraine, ensuring the supply of medicines is becoming more crucial and urgent each day and some medicines are already no longer available. That is why Dr. Falk Pharma will support an initiative by the humanitarian aid organization APOTHEKER HELFEN e.V., an initiative that is also supported by the European Crohn's and Colitis Organisation (ECCO) as well as the patient organization European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA). Via their network and supply infrastructure, and working together with gastroenterologists and healthcare facilities, APOTHEKER HELFEN e.V. aims to ensure a basic medical care for patients suffering from IBD by providing them with urgently required medicines. Dr. Falk Pharma is grateful for such an opportunity to help Ukrainian patients with a donation of its medicines.

#### **About Dr. Falk Pharma GmbH**

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France and Switzerland. Dr. Falk Pharma GmbH employs approximately 990 individuals globally and 218 in Freiburg.

Further information on Dr. Falk Pharma can be found online: <https://drfalkpharma.com>



Press release

Contact

**Dr. Falk Pharma GmbH**

Babette Kopp

Corporate Communications

Leinenweberstr. 5

79108 Freiburg

Germany

Phone: +49 761 1514-0

Email: [babette.kopp@drfalkpharma.de](mailto:babette.kopp@drfalkpharma.de)

[www.drfalkpharma.de](http://www.drfalkpharma.de)